← Back to Search

FOLFOXA for Pancreatic Cancer

Phase 2
Waitlist Available
Led By Howard Safran, MD
Research Sponsored by howard safran
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 3 years.
Awards & highlights

Study Summary

This trial will test if FOLFOX-A, a new chemotherapy regimen, is better than the standard of care, FOLFIRINOX, for patients with resected pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 3 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 3 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of Adjuvant FOLFOX-A
Secondary outcome measures
Disease-free Survival

Side effects data

From 2022 Phase 2 trial • 25 Patients • NCT02022033
84%
Peripheral sensory neuropathy
72%
Fatigue
64%
Nausea
60%
Alkaline phosphatase increased
56%
Weight loss
56%
Anemia
56%
Hypokalemia
56%
Alopecia
52%
Neutrophil count decreased
48%
Hypertension
40%
Diarrhea
40%
Platelet count decreased
40%
White blood cell decreased
36%
Alanine aminotransferase increased
36%
Pain
36%
Mucositis
36%
Aspartate aminotransferase increased
32%
Infections and infestations
32%
Lymphocyte count decreased
32%
Vomitting
28%
Myalgia
24%
Anorexia
24%
Insomnia
20%
Constipation
20%
Dehydration
20%
Dysgeusia
16%
Arthralgia
16%
Edema
16%
Infusion related reaction
16%
Flatulence
16%
Rash acneiform
16%
Hyponatremia
16%
Dizziness
12%
Cough
12%
Chills
12%
Nail discoloration
12%
Headache
12%
Hypoalbuminemia
8%
Generalized muscle weakness
8%
Anxiety
8%
Hiccups
8%
Fall
8%
Bloating
8%
Bone pain
8%
Hoarseness
8%
Sore throat
8%
Urinary urgency
4%
Nail Loss
4%
Urticaria
4%
Hypotension
4%
Amnesia
4%
Conjunctivitis
4%
Wound complication
4%
Creatinine increased
4%
Congestion
4%
Depression
4%
Musculoskeletal and Connective tissue disorder
4%
Presyncope
4%
Rash maculo-papular
4%
Dyspnea
4%
Atelectasis
4%
Tinnitus
4%
Flu like symptoms
4%
Dry skin
4%
Allergic rhinitis
4%
Gait disturbance
4%
Gastritis
4%
Hypocalcemia
4%
Sinus disorder
4%
Skin and subcutaneous tissue disorders
4%
Telangiectasia
4%
Blurred vision
4%
Dyspepsia
100%
80%
60%
40%
20%
0%
Study treatment Arm
FOLFOXA

Trial Design

1Treatment groups
Experimental Treatment
Group I: FOLFOXAExperimental Treatment1 Intervention
Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days. Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FOLFOXA
2014
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

howard safranLead Sponsor
8 Previous Clinical Trials
161 Total Patients Enrolled
Brown UniversityLead Sponsor
456 Previous Clinical Trials
558,319 Total Patients Enrolled
Howard Safran, MDPrincipal InvestigatorBrUOG
30 Previous Clinical Trials
908 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
howard safran 2014. "BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02022033.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top